Latest University of Texas Health Science Center at Houston Stories
Thousands of men are afflicted with an embarrassing and painful condition that triggers spontaneous, long-lasting erections.
Scientists working to develop a vaccine for the human immunodeficiency virus (HIV) report they have created the first antigen that induces protective antibodies capable of blocking infection of human cells by genetically-diverse strains of HIV.
In a development that could lead to a novel approach to the treatment of a devastating lung disease, biochemists at The University of Texas Health Science Center at Houston report they are the first to link the osteopontin (OPN) protein to chronic obstructive pulmonary disease (COPD).
New research at The University of Texas Health Science Center at Houston suggests that ancient Chinese herbal formulas used primarily for cardiovascular indications including heart disease may produce large amounts of artery-widening nitric oxide.
We've all seen video of astronauts drifting and gliding gracefully around inside the International Space Station like fish in a fishbowl.
The aggressiveness of tumors and their susceptibility to chemotherapy may become easier to predict based on a mathematical model developed at The University of Texas Health Science Center at Houston.
New research supports the findings of a landmark drug comparison study published in 2002 in which a diuretic drug or â€œwater pillâ€ outperformed other medications for high blood pressure. A scientific team including investigators from The University of Texas Health Science Center at Houston reports the findings in the May 11 issue of the Archives of Internal Medicine.
A breakthrough strategy to improve the effectiveness of the only tuberculosis vaccine approved for humans provided superior protection against the deadly disease in a pre-clinical test.
Positron Corporation (OTC: POSC) (the "Company") announced today that it has acquired an exclusive license to a coronary disease reversal and prevention practice management program created by K. Lance Gould, M.D. and the University of Texas Health Science Center at Houston.
In an article featured on the cover of the March issue of â€œNature Nanotechnology,â€ Mauro Ferrari, Ph.D., of The University of Texas Health Science Center at Houston presented a proof-of-concept study on a new multistage delivery system (MDS) for imaging and therapeutic applications. This discovery could go a long way toward making injectable drugs more effective. The study is included in the March 2 Advance Online Publication on Nature Nanotechnology.